Prothena Grabbing At Chunk Of $19B Immunotherapy Market: CEO Exclusive – Investor’s Business Daily
Investor’s Business Daily |
Prothena Grabbing At Chunk Of $19B Immunotherapy Market: CEO Exclusive
Investor’s Business Daily We have been working in the area of immunotherapy for a long time, so I continue to see exciting developments on the horizon for immunotherapy — in oncology and beyond. IBD: Does Prothena have any key launches or clinical trial data coming in 2017? |
